RT Journal Article
SR Electronic
T1 Beneficial changes in the gut microbiome of patients with multiple sclerosis after consumption of Neu-REFIX B-glucan in a clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.07.23295172
DO 10.1101/2023.09.07.23295172
A1 Dedeepiya, Vidyasagar Devaprasad
A1 Vetrievel, Chockanathan
A1 Ikewaki, Nobunao
A1 Yamamoto, Naoki
A1 Kawashima, Hiroto
A1 Ichiyama, Koji
A1 Senthilkumar, Rajappa
A1 Preethy, Senthilkumar
A1 Abraham, Samuel JK
YR 2023
UL http://medrxiv.org/content/early/2023/09/08/2023.09.07.23295172.abstract
AB Background Multiple sclerosis (MS) is a debilitating demyelinating disease and recent evidences are giving cues towards correlation of disease severity to gut microbiome dysbiosis. However, there haven’t been any reported interventions that beneficially modifies the gut microbiome to yield a clinically discernible improvement. Having earlier reported the clinical effects of a biological response modifier beta-glucan (BRMG) produced by the N-163 strain of Aureobasidum pullulans, commercially available as Neu-REFIX, which decreased the biomarkers of inflammation and produced beneficial immune-modulation in twelve MS patients in 60 days, we evaluated their gut microbiome in the present study.Methods Twelve patients diagnosed with MS participated in the study. Each consumed 16 g gel of the NEU-REFIX beta-Glucan for 60 days. Whole genome metagenomic sequencing was performed on the fecal samples before and after Neu-REFIX intervention.Results Post-intervention analysis showed that Actinobacteria followed by Bacteroides was the major family. Abundance of beneficial genera such as Bifidobacterium, Collinsela, Prevotella, Lactobacillus and species such as Prevotella copri (p-value=0.4), Bifidobacterium longum (p-value=0.2), Faecalibacterium prausnitzii (p-value=0.06), Siphoviridae (p-value=0.06) increased while inflammation associated genera such as Blautia (p-value=0.06), Ruminococcus (p-value=0.007) and Dorea (p-value = 0.03) decreased in abundance.Conclusion Restoration of gut eubiosis in terms of both increase in abundance of the good microbiome and suppression of the harmful ones which also correlate with earlier reported clinical improvement in MS patients makes this Neu-REFIX beta-glucan, a potential disease modifying therapy (DMT) requiring larger studies for validation in MS and other auto-immune-inflammatory conditions where a safe intervention for immune modulation is vital.Competing Interest StatementAuthor Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an inventor to several patents of relevance to these beta glucans.Clinical TrialClinical trials registry of India, CTRI/2022/05/042497Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Universal Ethics Committee (A Unit of Aurous HealthCare Research and Development India Pvt. Ltd)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data generated or analysed during this study are included in the article itself.